Dana-Farber Cancer Institute | Strategic Alliance Partners

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Toni Choueiri, MD, discusses data from LITESPARK-022 in ccRCC.

A triplet combination regimen led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm.

Toni Choueiri, MD, discusses how he will utilize adjuvant belzutifan plus pembrolizumab in ccRCC after its FDA approval.

Matthew S. Davids, MD, MMSc, discusses how efficacy data for pirtobrutinib plus venetoclax and rituximab from BRUIN CLL-322 may affect relapsed/refractory CLL management.

Praful Ravi, MB, BChir, MRCP, discusses the design of the PSMAtrack study of changes in PSMA-PET during initial therapy in patients with mHSPC.

Praful Ravi, MB, BChir, MRCP, discusses the clinical utility of PSMA-PET in mHSPC.

Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.

Praful Ravi, MB, BChir, MRCP, discusses data from the phase 4 PSMAtrack trial in mHSPC.

Promising data for zenocutuzumab in patients with advanced NRG1-positive cholangiocarcinoma were shown according to researchers at Dana-Farber.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

Alicia Morgans, MD, MPH, discusses the clinical significance of data from the phase 2 ARACOG trial in prostate cancer.

Alicia Morgans, MD, MPH, discusses data on the cognitive effects of enzalutamide vs darolutamide in prostate cancer from the ARACOG trial.

Alicia Morgans, MD, MPH, discusses the background of the ARACOG trial in prostate cancer.

Sara M. Tolaney, MD, MPH, highlights the FDA approval of sacituzumab govitecan plus pembrolizumab for first-line TNBC management.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Sara M. Tolaney, MD, MPH, discusses an analysis of depth of response in HER2-positive advanced/metastatic breast cancer treated with T-DXd plus pertuzumab.

Toni Choueiri, MD, discusses the significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

Alicia Morgans, MD, MPH, discusses findings from ARACOG trial of the cognitive effects of darolutamide vs enzalutamide in prostate cancer.

Dana-Farber investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial in smoldering myeloma.

Glenn J. Hanna, MD, highlights interim efficacy and safety data from a phase 1 trial of Emi-Le in patients with aggressive adenoid cystic carcinoma.

Ficerafusp alfa plus pembrolizumab generated a 54% ORR and 21.7-month median DOR in first-line HPV-negative recurrent or metastatic HNSCC.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

The Yawkey Foundation made a $50 million grant to support Dana-Farber's planned cancer hospital and the Future of Cancer Care Fund.

Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer.

Magnolia Contreras, MSW, MBA, of Dana-Farber Cancer Institute, was honored with The Lemuel Shattuck Award for Significant Contributions to Public Health Practice.

A small clinical trial led by Dana-Farber Cancer Institute builds on Salk Institute’s foundational research on vitamin D receptor and tumor microenvironment